DNase I

DNase I Molekülinformation

Englischer Name	Deoxyribonuclease 1	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1	Target-Alias	EC:3.1.21.1，Deoxyribonuclease I，Dornase alfa，DNase I， Lysosomal，DNase I，DNL1，DNASE1，Deoxyribonuclease 1，DRNI，Human Urine Deoxyribonuclease I，Deoxyribonuclease-1，EC 3.1.21.1
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Deoxyribonuclease 1
Target-Alias	EC:3.1.21.1，Deoxyribonuclease I，Dornase alfa，DNase I， Lysosomal，DNase I，DNL1，DNASE1，Deoxyribonuclease 1，DRNI，Human Urine Deoxyribonuclease I，Deoxyribonuclease-1，EC 3.1.21.1
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	1
Höchste Forschungs- und Entwicklungsphase	Approved

DNase I Produktliste

Attribut
Kits (1)
Produktbibliothek
Online (1)
Spezies
Bovine (1)
Etikett
- (1)
Marker
- (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
HOT ASE-A002	Bovine	-	resDetect™ DNase Activity Assay Kit (Fluorescence)				In den Warenkorb legen

Gesamtmenge1

DNase I Molekülhintergrund

Serum endocuclease secreted into body fluids by a wide variety of exocrine and endocrine organs. Expressed by non-hematopoietic tissues and preferentially cleaves protein-free DNA (By similarity). Among other functions, seems to be involved in cell death by apoptosis. Binds specifically to G-actin and blocks actin polymerization. Together with DNASE1L3, plays a key role in degrading neutrophil extracellular traps (NETs) (By similarity). NETs are mainly composed of DNA fibers and are released by neutrophils to bind pathogens during inflammation (By similarity).

DNase I Molekülalias

DNase I,Deoxyribonuclease-1,Deoxyribonuclease I

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
repurposed deoxyribonuclease I (Human Microbiology Institute)		Clinical		Alzheimer Disease	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Chorionic Gonadotropin	LDI-200	Approved	Angiogene Pharmaceuticals						Prostatic Neoplasms; Leukemia, Myeloid, Acute; Infertility, Female; Hypogonadism; Cryptorchidism	Details